Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Trial Profile

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Lenalidomide; Rituximab
  • Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 13 Nov 2023 Planned End Date changed from 25 Aug 2023 to 29 Dec 2028.
    • 13 Dec 2022 Results (n=67 from R/R relapse and refractory and TN treatment naive Follicular lymphoma cohorts) assessing efficacy and safety of Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 01 Oct 2022 Results (n=43) assessing efficacy and safety of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma, published in the British Journal of Haematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top